+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 10 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating whether calderasib combined with subcutaneous pembrolizumab can better treat non-small cell lung cancer NSCLC with the KRAS G12C mutation. The study compares this combination to pembrolizumab with chemotherapy to see if it helps patients live longer without their cancer growing or spreading. This is a phase 3 clinical trial assessing treatment effectiveness and safety in participants with advanced or metastatic nonsquamous NSCLC. Participants will be randomly assigned to one of two groups. One group receives pembrolizumab plus berahyaluronidase alfa as a subcutaneous injection every 6 weeks for up to 18 cycles about 2 years, along with calderasib tablets until treatment discontinuation. The other group receives pembrolizumab plus berahyaluronidase alfa with chemotherapy drugs pemetrexed and either carboplatin or cisplatin given intravenously on specified days in the first cycles, also until discontinuation criteria are met. During the study, participants will have regular assessments including tumor scans and health questionnaires to monitor progression free survival, overall survival, response rates, and quality of life. Adverse events and treatment tolerability will also be tracked up to approximately 81 months. The study aims to provide detailed information on the impact of these treatments on cancer progression and patient well-being over time.

Age: 18Years +All GendersPhase 3
221 locations
S

Actively Recruiting

Researchers are evaluating new treatment options for people with locally advanced, unresected non-small cell lung cancer NSCLC that has a KRAS G12C gene mutation. This trial aims to learn if combining calderasib MK-1084 with durvalumab, an immunotherapy, after chemotherapy and radiation can help patients live longer without their cancer growing or spreading. Participants will be randomly assigned to receive either calderasib along with durvalumab or a placebo with durvalumab. Calderasib is taken as an oral tablet, while durvalumab is given by intravenous infusion. The study is blinded so neither participants nor researchers know who receives the active drug or placebo during treatment. During the study, participants will be monitored regularly to assess cancer progression, survival, quality of life, and side effects. This includes tumor testing, blood work, and questionnaires over up to approximately 6 years for progression-free survival and up to 9 years for overall survival and other health measures. The study is sponsored by Merck Sharp & Dohme LLC and follows participants from screening through long-term follow-up.

Age: 18Years +All GendersPhase 3
107 locations
I

Actively Recruiting

Researchers are evaluating the safety, tolerability, pharmacokinetics, and early antitumor activity of the drug BG-C0979 alone or combined with tislelizumab in adults with certain advanced solid tumors. This first-in-human study includes Phase 1a, focusing on dose escalation and safety expansion, and Phase 1b, which involves dose optimization and expansion. The study is sponsored by BeOne Medicines and aims to find safe and effective doses for future research. Participants will receive BG-C0979 through intravenous infusion. In Phase 1a, doses are gradually increased to find safe levels, followed by safety expansion at selected doses. In Phase 1b, participants receive optimized doses of BG-C0979 alone or in combination with tislelizumab for selected tumor types. The study includes multiple treatment groups, each with specific dosing plans and evaluation periods lasting up to approximately 24 months. During the study, participants will undergo regular assessments including imaging to measure tumor response, laboratory tests, and monitoring of side effects. Researchers will track drug levels in blood and evaluate measures like overall response rate, duration of response, disease control rate, and progression-free survival. This comprehensive monitoring will continue for up to two years to evaluate safety and preliminary effectiveness of the treatments.

Age: 18Years +All GendersPhase 1
18 locations
G

Actively Recruiting

Researchers are evaluating the safety and clinical activity of EIK1001, a drug that targets Toll like receptor 78, given intravenously with pembrolizumab and chemotherapy in patients with stage 4 non-small cell lung cancer NSCLC. This global, multicenter, double-blind, placebo-controlled study involves participants who have not received prior systemic therapy and aims to assess treatment effects in both squamous and non-squamous NSCLC types. The trial is conducted in two phases Phase 2 and Phase 3 and includes dose optimization, dose expansion, and confirmatory hypothesis testing. Participants are randomly assigned to one of three groups EIK1001 at one of two selected doses plus standard chemotherapy and pembrolizumab, or placebo plus standard chemotherapy and pembrolizumab. Chemotherapy regimens differ based on tumor histology, with pemetrexed plus carboplatin or cisplatin for non-squamous NSCLC, and carboplatin plus paclitaxel or nab-paclitaxel for squamous NSCLC. Treatments are administered intravenously, and the study is designed to evaluate safety and efficacy over time. During the study, participants undergo regular assessments to monitor progression-free survival, overall survival, and objective response, which are tracked for up to 6 to 10 years depending on the measure. Additional evaluations include adverse event incidence and duration of response. Participants are monitored closely with clinical visits throughout the study period, which may last several years, to ensure safety and collect data on treatment effects.

Age: 18Years +All GendersPhase 2Phase 3
42 locations
E

Actively Recruiting

Researchers are evaluating BG-C477, a targeted antibody-drug conjugate, in adults with advanced solid tumors that cannot be removed by surgery or have spread to other parts of the body. This Phase 1ab study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and early antitumor activity of BG-C477 alone and in combination with other anticancer agents. BG-C477 targets a protein called CEA on lung cancer cells to deliver a drug that prevents cancer cell multiplication and causes cell death. The study includes two parts Phase 1a tests increasing doses of BG-C477 alone to find a safe dose without serious side effects. Phase 1b evaluates the selected dose further, either alone or combined with chemotherapy or tislelizumab. BG-C477 is administered intravenously. Participants receive treatment during these phases, with sequential dose escalation and expansion cohorts. The treatment duration is about 9 months for Phase 1a and approximately 18 months for Phase 1b. Participants will attend regular clinic visits for treatment administration, health assessments, blood tests, tumor evaluations, and imaging studies. Researchers will monitor adverse events, determine the recommended dose levels, and assess tumor response and progression using standardized criteria. Safety and pharmacokinetic data will be collected up to about two years after the last dose. Overall participation lasts up to 18 months depending on the study phase.

Age: 18Years +All GendersPhase 1
59 locations
L

Actively Recruiting

Heart attacks occur when a blood clot blocks the hearts blood vessels, stopping blood flow to the heart muscle. This trial focuses on patients with ST-elevation myocardial infarction STEMI and looks at how microcirculatory damage can be measured using the Index of Microcirculatory Resistance IMR. The study aims to find out if treating patients with impaired microcirculatory perfusion using low-dose intracoronary thrombolytic therapy can reduce heart muscle damage and improve clinical outcomes. Participants who have had a heart attack and undergone angioplasty will have their IMR measured. Those with an IMR above 32 will be randomly assigned to receive either low-dose tenecteplase a clot-dissolving drug or a placebo sterile water administered directly into the coronary artery. Patients with lower IMR will be followed in a registry. The treatment is given as an intracoronary infusion over 3 minutes. Cardiac enzymes, MRI scans, and other heart function tests will be done at various time points. During the study, participants will have heart enzyme tests at hospital admission and discharge. Those in the randomised group will receive cardiac MRI scans at discharge and six months later. Follow-up visits will occur at 30 days, then 6, 12, and 24 months after discharge to monitor heart function, rehospitalisation, and mortality. The main outcomes measured include cardiovascular death, heart failure rehospitalisation, heart attack size, and bleeding events, with safety and efficacy monitored closely throughout the study period.

Age: 18Years +All GendersPhase 3
22 locations
S

Actively Recruiting

Kidney failure is a serious health problem that requires treatment with dialysis or transplantation to survive. Haemodialysis, the most common treatment, can cause symptoms like fatigue, pain, cramps, and poor quality of life, with less than 60% of full health reported by patients. Early mortality rates are high, especially in the first 3 to 6 months after starting haemodialysis at the usual three sessions per week. This trial investigates whether starting haemodialysis incrementally at two sessions per week preserves quality of life and kidney function better than conventional treatment. The study compares two approaches incremental haemodialysis, where participants begin with two sessions per week and increase to three sessions only if needed, and conventional haemodialysis, where participants start with three sessions per week from the beginning. This randomized, open-label trial will recruit 372 participants across centers in Australia and Canada. The goal is to assess if the incremental method is a safe, practical, and cost-effective alternative that reduces the physical and financial burdens of dialysis. Participants will be followed for up to 18 months, with quality of life assessed at 6 months using the Kidney Disease Quality of Life Short Form questionnaire as the primary measure. Additional assessments include kidney function, healthcare use and costs, mortality, hospital admissions, symptoms, fatigue, nutritional status, and vascular access, collected at regular intervals. The study will monitor safety and side effects throughout the trial period to provide comprehensive data on the impacts of both dialysis approaches.

Age: 18Years +All GendersPhase Not Applicable
18 locations
S

Actively Recruiting

Researchers are evaluating the use of adjuvant calderasib combined with subcutaneous pembrolizumab and berahyaluronidase alfa MK-3475A compared to adjuvant placebo plus MK-3475A in participants with completely resected stage IIA-IIIB N2, KRAS G12C-mutant non-small cell lung cancer. This phase 3, randomized, double-blind study focuses on participants who have previously received either neoadjuvant pembrolizumab plus chemotherapy or adjuvant chemotherapy. The main goal is to compare disease-free survival between the treatment groups. Participants are assigned to one of two groups one group receives daily calderasib and MK-3475A every six weeks for up to nine doses, while the other group receives a daily placebo plus MK-3475A on the same schedule. The study treatments are administered as oral tablets for calderasib or placebo, and subcutaneous injections for MK-3475A. Treatment continues for up to nine doses or until disease progression or other criteria are met. During the study, participants will undergo regular assessments including imaging scans such as contrast-enhanced chest or abdomen CT or MRI to confirm no evidence of disease before starting treatment. Researchers will monitor disease-free survival up to approximately 11 years, along with overall survival, lung cancer specific survival, distant metastasis-free survival, quality of life measures, and safety outcomes. Adverse events and treatment discontinuations will be tracked for up to 13.5 years, ensuring long-term safety and efficacy monitoring.

Age: 18Years +All GendersPhase 3
120 locations
A

Actively Recruiting

Researchers are evaluating multiple treatments for community-acquired pneumonia and other respiratory tract infections in hospitalized patients admitted to intensive care. This adaptive platform trial, called REMAP-CAP, aims to identify the effects of various interventions on patient outcomes, including survival and recovery. It also serves as a flexible research platform to study treatments during respiratory pandemics such as COVID-19, with a specific sub-platform called REMAP-COVID for evaluating COVID-19 treatments in the United States. Participants are randomized to receive one or more interventions from various treatment domains including antibiotics, corticosteroids, antivirals, immune modulators, anticoagulation strategies, and mechanical ventilation approaches. Some interventions have been closed to recruitment while others remain active, and dosing or duration often follows local clinical guidelines or specific protocols. The trial uses an adaptive design that allows modification of treatment assignments based on accumulating data and can study interactions between treatments across domains. During the study, hospitalized patients with respiratory infections will be monitored and assessed for outcomes such as 90-day survival and recovery trajectories, days alive without organ support, and quality of life at six months. Data collected include treatment responses, hospital discharge status, and mortality. The trial is designed to continue enrolling patients adaptively over time, with ongoing evaluation of multiple interventions until conclusive answers about their effects are reached.

Age: 28Days +All GendersPhase 3
408 locations
R

Actively Recruiting

Researchers are evaluating whether casdatifan combined with cabozantinib can improve progression-free survival compared to placebo plus cabozantinib in patients with advanced or metastatic clear cell renal cell carcinoma. The study focuses on patients who have previously received anti-PD-1 or anti-PD-L1 therapies in their most recent treatment, with no more than one prior metastatic treatment regimen. This is a randomized, double-blind, active-controlled phase 3 trial aimed at advancing treatment options for this patient group. Participants will be randomly assigned to receive either casdatifan and cabozantinib or placebo and cabozantinib, both taken orally. The study includes two treatment arms one experimental arm with casdatifan and cabozantinib, and a comparator arm with placebo and cabozantinib. Treatment is ongoing, with monitoring for up to approximately 33 months for key outcomes, and follow-up for overall survival up to about 64 months. Throughout the study, participants will undergo regular assessments including imaging scans evaluated by a blinded independent review to measure tumor response and progression. Researchers will track progression-free survival, overall survival, response rates, duration of response, disease control, and treatment-related adverse events. Symptom changes will also be monitored using patient-reported measures. The total participation duration may extend up to several years to capture long-term outcomes and safety data.

Age: 18Years +All GendersPhase 3
191 locations